True To Its Cancer Focus, Medarex Outlicenses C. Diff Therapy To Merck
Medarex and partner Massachusetts Biologic Laboratories will split equally $60 million upfront and potential milestones worth $165 million.
Medarex and partner Massachusetts Biologic Laboratories will split equally $60 million upfront and potential milestones worth $165 million.